CKD-501 + D759 + D150

CKD-501 + D759 + D150 is an investigational **oral combination therapy for type 2 diabetes mellitus** under development by Chong Kun Dang. The combination assesses the addition of **CKD-501 (lobeglitazone, a thiazolidinedione and PPAR gamma agonist)** to background therapy with **D759 and D150**—the latter two are company code names likely representing other antihyperglycemic agents, though their exact identities are not definitively matched in public databases. Lobeglitazone (CKD-501) increases insulin sensitivity via PPAR gamma activation, while the other agents are hypothesized to provide *complementary glucose-lowering mechanisms*. The combination's primary clinical goal is improving glycemic control (HbA1c reduction) and metabolic parameters in patients with type 2 diabetes, with safety and efficacy evaluated in randomized controlled trials[2][3][4]. Direct evidence for chronic kidney disease (CKD) protection is not established, though triple-agent strategies are increasingly studied in metabolic syndrome and diabetic cohorts.

Other names

CKD-501 added to D150 plus D759CKD501 added to D150 plus D759CKD 501 added to D150 plus D759CKD 383 (for similar fixed combination with D745 per AdisInsight, not identical)CKD-501/D745/D150/D029 (as a close alternative, see comments)